Study summary

A KLK2-targeted T-cell engager lowered PSA by half in about 4 in 10 men

Pasritamig first-in-human trial · 174 men, phase 1 · Published August 2025, Journal of Clinical Oncology

42.4%had PSA fall by at least half (recommended dose)

What was tested

Pasritamig, a bispecific antibody that links immune T cells to the KLK2 protein on prostate cancer cells, in heavily treated castration-resistant disease. No comparison group.

What they found

What it means

Now in a phase 3 trial for late-line disease.

J Clin Oncol, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.